PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

Pancreatic cancer (PC) is one of the tumors with the lowest survival rates due to the poor efficacy of the treatments currently used. Gemcitabine (GMZ), one of the chemotherapeutic agents employed when the tumor is unresectable, frequently fails due to the development of drug resistance. PARP1 is a...

Full description

Bibliographic Details
Main Authors: Francisco Quiñonero, Cristina Mesas, Jose A. Muñoz-Gámez, Cristina Jiménez-Luna, Gloria Perazzoli, Jose Prados, Consolación Melguizo, Raul Ortiz
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Biomedicine & Pharmacotherapy
Subjects:
PARP1
Pancreatic cancer
Olaparib
Gemcitabine
Drug resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222010587

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222010587

Similar Items